Report
(Sponsored) Oncodesign Precision Medicine - EUR 5.6m public funding to advance OPM-101 for ICI-AC
Last night, OPM announced receival of EUR 5.6m public funding (France 2030) for its DEMOCRITE Project dedicated to clinical development of its RIPK2 inhibitor ‘OPM-101' for immune checkpoint inhibitor-associated colitis (ICI-AC).Funds strengthen OPM's latest net cash position (EUR 6.8m) and allows OPM to further advance the Ph2a for ICI-AC with OPM-101 (expected to start towards end of this year). In parallel, the company will explore the potential of the asset for inflammatory bowel disease (IBD) as well in 2025.We consider it wise to prioritize development in said indication given the scientific rationale, preclinical data, and unmet need for new effective
Underlying
Oncodesign Precision Medicine
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.